Fate Therapeutics Inc

NASDAQ:FATE   3:59:59 PM EDT
109.01
-5.30 (-4.64%)
4:09:50 PM EDT: $108.96 -0.05 (-0.05%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)10.07B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$5.02 Million
Adjusted EPS-$0.39
See more estimates
10-Day MA$109.93
50-Day MA$81.60
200-Day MA$46.62
See more pivots

FATE THERAPEUTICS INC Stock, NASDAQ:FATE

3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO, CA 92121
United States of America
Phone: 858.875.1803
Number of Employees: 104

Description

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy that consists of adaptive memory NK cells; engineered hnCD16 induced pluripotent stem cells (iPSC)-derived natural killer cell therapy candidates for hematologic/solid tumors; and engineered chimeric antigen receptor iPSC-derived T cell therapy product candidates for hematologic/solid tumors. The company's immuno-regulation product candidates comprise ProTmune, an investigational programmed cellular immunotherapy for use as a next-generation allogeneic hematopoietic cell transplantation cell graft; and ToleraCyte for the treatment of autoimmune and inflammatory diseases; engineered iPSC-derived CD34+ cell therapy for immune disorders. Fate Therapeutics, Inc. has a research collaboration and license agreement with Memorial Sloan Kettering Cancer Center to develop off-the-shelf T-cell immunotherapies; and strategic research collaboration and license agreement with Juno Therapeutics, Inc. to identify small molecule modulators that enhance the function of T cells. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.